Authors


Samantha DiGrande

Latest:

AAM's Christine Simmon on Biosimilars Council Initiatives and Educating Around Interchangeability

After the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.



Kaitlynn Ely

Latest:

Rituximab Induction Is Cost Effective for Asymptomatic Advanced Follicular Lymphoma

Rituximab induction therapy has the highest probability of cost effectiveness in treating newly diagnosed patients with asymptomatic advanced follicular lymphoma, according to a study published in the British Journal of Haematology.


Joseph P. Fuhr, PhD

Latest:

Expect Shakeout Amid Biosimilar Market Growth

The biosimilar market is headed for a fork in the road, and the road taken will lead to savings and access or less competition and stiffer regulation.


Christina Mattina

Latest:

Califf Wins Narrow Senate Vote for Second Turn as FDA Commissioner

In a 50-46 vote, the Senate confirmed Robert Califf, MD, as President Biden’s FDA commissioner. The agency has been without a permanent leader for more than a year.



The Center for Biosimilars

Latest:

Novartis to Make Sandoz a Stand-alone Company

The move will create Europe's largest generics company.


Ross Shahinian

Latest:

COVID-19's Multifaceted Effect on Biosimilars

The coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.






Sandeep Sangwan, MPharm

Latest:

COVID-19's Multifaceted Effect on Biosimilars

The coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.








Gianna Melillo

Latest:

Coherus Banks on 2022 Approvals After Net Losses for Q4, 2021

Coherus released its earnings report for the last quarter of 2021 and for the year as a whole.


Marcus H. Snow, MD

Latest:

Dr Marcus H. Snow: The US Launch of Renflexis

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.


Allison Inserro

Latest:

FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).


Stanton R. Mehr

Latest:

Ritumixab Biosimilar Demonstrates Positive Results in Rheumatoid Arthritis

Pharmacokinetics of CT-P10 were highly similar to originator products.


Chad Landmon, JD

Latest:

Legal Opinion: BPCIA Is Likely to Survive Latest ACA Challenge

Intellectual property attorneys discuss the Supreme Court oral arguments over the Affordable Care Act (ACA) and implications for the Biologics Price Competition and Innovation Act (BPCIA).


Sara Karlovitch

Latest:

What's Ahead for Biosimilar Litigation?

What is ahead for biosimilar litigation? We highlight a recent interview Goodwin partners gave recently about their new guide to biosimilar litigation.


Christina Corridon, MPH, MBA

Latest:

COVID-19's Multifaceted Effect on Biosimilars

The coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.


Daniella Latham

Latest:

Naming Biosimilars: The Debate Rages On

As one of Shakespeare’s most famous characters asked, "What’s in a name?”, the answer in the biosimilars industry is clear: nomenclature is critical for identification purposes.


Jackie Syrop

Latest:

Study Finds ABP 215 and Bevacizumab Demonstrate PK Similarity in Japanese Men

The researchers say that their data were consistent with the pharmacokinetic equivalence previously demonstrated in a single-dose PK study that included 202 healthy adult men in the United States and European Union, and thus add to the evidence of ABP-215 as a high-quality biosimilar to bevacizumab for use in Japan.



© 2024 MJH Life Sciences

All rights reserved.